NNNN

Anbio Biotechnology operates within the healthcare sector, specifically in the medical instruments and supplies industry. With a market capitalization of $1.50 billion, this company is relatively small compared to others in its sector, generating revenue of $6.92 million on an annual basis. Anbio has a workforce of 27 employees. The financial health of Anbio Biotechnology reveals notable profitability metrics. The company boasts gross, operating, and profit margins of 89.7%, 73.4%, and 37.2% respectively. In terms of returns, the return on equity (ROE) stands at 11.2%, while the return on assets (ROA) is 4.7%. Anbio's cash balance totals $13.43 million, but debt information is not available. Anbio Biotechnology has a price-to-earnings ratio of 488.57 and exhibits revenue growth of -21.6% year-over-year, with earnings growth at 2.8%. The dividend yield is not applicable as the payout ratio is 0.0%.